EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence

Francesca Mancinetti, Virginia Boccardi iD, Marta Valenza iD, Martina Alunno, Michela Scamosci, Roberta Facchinetti, Veronica Tecchio, Anna Giulia Guazzarini iD, Martina Procaccini, Luigi Cari iD, Giuseppe Nocentini iD, Carmelinda Ruggiero iD und 3 weitere

Nutrients · 2026

DOI: 10.3390/nu18182949 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Francesca Mancinetti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy. Hauptthemen laut MEDLINE: Luteolin, Palmitic Acids, Ethanolamines, Cognitive Dysfunction. Die Arbeit nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cognitive decline is closely associated with biological aging and with interconnected processes, including chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and cellular senescence. Nutraceutical strategies capable of modulating several of these pathways may represent a complementary approach to supporting cognitive health. This narrative review examines the biological rationale and available evidence regarding palmitoylethanolamide (PEA), luteolin, and their co-ultramicronized formulation (PEA-Lut) in cognitive impairment and dementia. Evidence from mechanistic studies, animal models, observational studies, and clinical trials was considered. PEA is an endogenous N-acylethanolamine with anti-inflammatory and neuroprotective properties, whereas luteolin exerts complementary antioxidant and anti-inflammatory effects. Co-ultramicronization may improve their physicochemical properties and biological activity. Preclinical studies suggest that PEA-Lut may attenuate glial activation, pro-inflammatory signaling, oxidative and nitrosative stress, and amyloid-β-induced cellular injury while supporting neurotrophic signaling and neuronal survival. Preliminary clinical findings have suggested possible benefits in stroke rehabilitation, frontotemporal dementia, and other neuroinflammatory conditions. However, human evidence specifically addressing mild cognitive impairment and Alzheimer’s disease remains limited, heterogeneous, and largely derived from preclinical and small or non-randomized studies. PEA-Lut therefore represents a biologically plausible investigational nutraceutical approach, although available clinical safety data are limited to relatively small and heterogeneous populations and short observation periods. Adequately powered randomized controlled trials are needed to determine its clinical efficacy, optimal timing and dosage, and long-term safety in individuals at risk of dementia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LuteolinPalmitic AcidsEthanolaminesCognitive DysfunctionBrainAgingHumansAnimalsAmidesNeuroprotective AgentsDietary SupplementsAnti-Inflammatory AgentsOxidative StressAntioxidantsCognitive Enhancement

Stichwörter der Autor:innen

agingcognitive declinecognitive impairmentluteolinneuroinflammationpalmitoylethanolamide

Substanzen

palmidrolLuteolinPalmitic AcidsEthanolaminesAmidesNeuroprotective AgentsAnti-Inflammatory AgentsAntioxidants

Autor:innen und Institutionen

  • Division of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
  • Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, 00185 Roma, Italy.
  • Department of Life Sciences, Health and Health Professions, Link Campus University, 00165 Roma, Italy.
  • Division of Pharmacology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
  • Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 77 Stockholm, Sweden.

ORCID-Profile: Virginia Boccardi, Marta Valenza, Anna Giulia Guazzarini, Luigi Cari, Giuseppe Nocentini, Carmelinda Ruggiero, Caterina Scuderi, Patrizia Mecocci

Zitieren

APA

Mancinetti, F., Boccardi, V., Valenza, M., Alunno, M., Scamosci, M., Facchinetti, R., Tecchio, V., Guazzarini, A. G., Procaccini, M., Cari, L., Nocentini, G., Ruggiero, C., Scuderi, C., Steardo, L., & Mecocci, P. (2026). Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence. Nutrients. https://doi.org/10.3390/nu18182949

Vancouver

Mancinetti F, Boccardi V, Valenza M, Alunno M, Scamosci M, Facchinetti R, et al. Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence. Nutrients. 2026. doi:10.3390/nu18182949

BibTeX
@article{Mancinetti2026,
  author = {Mancinetti, Francesca and Boccardi, Virginia and Valenza, Marta and Alunno, Martina and Scamosci, Michela and Facchinetti, Roberta and Tecchio, Veronica and Guazzarini, Anna Giulia and Procaccini, Martina and Cari, Luigi and Nocentini, Giuseppe and Ruggiero, Carmelinda and Scuderi, Caterina and Steardo, Luca and Mecocci, Patrizia},
  title = {Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18182949}
}
Kostenlos starten →